|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: PAOX |
Gene summary for PAOX |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | PAOX | Gene ID | 196743 |
| Gene name | polyamine oxidase | |
| Gene Alias | PAO | |
| Cytomap | 10q26.3 | |
| Gene Type | protein-coding | GO ID | GO:0006576 | UniProtAcc | Q6QHF9 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 196743 | PAOX | HCC1_Meng | Human | Liver | HCC | 2.14e-07 | 5.19e-03 | 0.0246 |
| 196743 | PAOX | HCC1 | Human | Liver | HCC | 7.57e-03 | 2.70e+00 | 0.5336 |
| 196743 | PAOX | HCC2 | Human | Liver | HCC | 6.44e-09 | 3.55e+00 | 0.5341 |
| 196743 | PAOX | S014 | Human | Liver | HCC | 7.92e-12 | 3.69e-01 | 0.2254 |
| 196743 | PAOX | S015 | Human | Liver | HCC | 8.76e-18 | 5.25e-01 | 0.2375 |
| 196743 | PAOX | S016 | Human | Liver | HCC | 8.79e-21 | 4.96e-01 | 0.2243 |
| 196743 | PAOX | S028 | Human | Liver | HCC | 1.30e-02 | 1.26e-01 | 0.2503 |
| 196743 | PAOX | S029 | Human | Liver | HCC | 5.20e-06 | 2.06e-01 | 0.2581 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00065961 | Liver | HCC | polyamine biosynthetic process | 12/7958 | 14/18723 | 1.17e-03 | 6.54e-03 | 12 |
| GO:00065951 | Liver | HCC | polyamine metabolic process | 14/7958 | 18/18723 | 2.57e-03 | 1.23e-02 | 14 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa041464 | Liver | HCC | Peroxisome | 58/4020 | 82/8465 | 1.57e-05 | 1.05e-04 | 5.85e-05 | 58 |
| hsa041465 | Liver | HCC | Peroxisome | 58/4020 | 82/8465 | 1.57e-05 | 1.05e-04 | 5.85e-05 | 58 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| PAOX | SNV | Missense_Mutation | novel | c.833T>C | p.Phe278Ser | p.F278S | Q6QHF9 | protein_coding | deleterious(0) | possibly_damaging(0.738) | TCGA-A7-A0CD-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
| PAOX | SNV | Missense_Mutation | rs754940986 | c.745A>C | p.Thr249Pro | p.T249P | Q6QHF9 | protein_coding | deleterious(0.02) | probably_damaging(0.968) | TCGA-AR-A1AP-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | anastrozole | SD |
| PAOX | SNV | Missense_Mutation | rs754940986 | c.745N>C | p.Thr249Pro | p.T249P | Q6QHF9 | protein_coding | deleterious(0.02) | probably_damaging(0.968) | TCGA-D8-A1X6-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | tamoxiphen | SD |
| PAOX | SNV | Missense_Mutation | c.696N>A | p.Met232Ile | p.M232I | Q6QHF9 | protein_coding | tolerated(0.43) | benign(0.001) | TCGA-E2-A10C-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | |
| PAOX | SNV | Missense_Mutation | rs754940986 | c.745A>C | p.Thr249Pro | p.T249P | Q6QHF9 | protein_coding | deleterious(0.02) | probably_damaging(0.968) | TCGA-E9-A1NG-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | letrozole | SD |
| PAOX | SNV | Missense_Mutation | rs754940986 | c.745N>C | p.Thr249Pro | p.T249P | Q6QHF9 | protein_coding | deleterious(0.02) | probably_damaging(0.968) | TCGA-EW-A1J5-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
| PAOX | SNV | Missense_Mutation | rs754940986 | c.745A>C | p.Thr249Pro | p.T249P | Q6QHF9 | protein_coding | deleterious(0.02) | probably_damaging(0.968) | TCGA-EW-A1PH-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD |
| PAOX | SNV | Missense_Mutation | novel | c.1174G>A | p.Glu392Lys | p.E392K | Q6QHF9 | protein_coding | deleterious(0) | probably_damaging(0.988) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| PAOX | SNV | Missense_Mutation | c.811N>C | p.Glu271Gln | p.E271Q | Q6QHF9 | protein_coding | deleterious(0.02) | possibly_damaging(0.858) | TCGA-C5-A1BF-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD | |
| PAOX | SNV | Missense_Mutation | c.319N>T | p.His107Tyr | p.H107Y | Q6QHF9 | protein_coding | tolerated(0.2) | probably_damaging(0.982) | TCGA-Q1-A73O-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |